Evidence map›Paper›PMID 32231662›Full record

ReviewFrontiers in immunology2020

Human Chorionic Gonadotrophin: New Pleiotropic Functions for an "Old" Hormone During Pregnancy.

Virginie Gridelet, Sophie Perrier d'Hauterive, Barbara Polese, Jean-Michel Foidart, Michelle Nisolle, Vincent Geenen

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Endometrial immune dysregulation shapes CD8Frontiers in immunology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Virginie GrideletGIGA-I3 Center of Immunoendocrinology GIGA Research Institute, University of Liege, Liege, Belgium.
Sophie Perrier d'HauteriveGIGA-I3 Center of Immunoendocrinology GIGA Research Institute, University of Liege, Liege, Belgium.
Barbara PoleseGIGA-I3 Center of Immunoendocrinology GIGA Research Institute, University of Liege, Liege, Belgium.
Jean-Michel FoidartLaboratory of Tumor and Development Biology, University of Liège, Liège, Belgium.
Michelle NisolleCenter for Assisted Medical Procreation, University of Liège, CHR Citadelle, Liège, Belgium.
Vincent GeenenGIGA-I3 Center of Immunoendocrinology GIGA Research Institute, University of Liege, Liege, Belgium.
University of Liège · BECentre hospitalier régional de la Citadelle · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human chorionic gonadotrophin (hCG) is the first specific molecule synthesized by the embryo. hCG RNA is transcribed as early as the eight-cell stage, and the blastocyst produces the protein before its implantation. hCG in the uterine microenvironment binds with its cognate receptor, luteinizing hormone/choriogonadotropin receptor (LHCGR), on the endometrial surface. This binding stimulates leukemia inhibitory factor (LIF) production and inhibits interleukin-6 (IL-6) production by epithelial cells of the endometrium. These effects ensure essential help in the preparation of the endometrium for initial embryo implantation. hCG also effects angiogenic and immunomodulatory actions as reported in many articles by our laboratories and other ones. By stimulating angiogenesis and vasculogenesis, hCG provides the placenta with an adequate maternal blood supply and optimal embryo nutrition during the invasion of the uterine endometrium. The immunomodulatory properties of hCG are numerous and important for programming maternal immune tolerance toward the embryo. The reported effects of hCG on uterine NK, Treg, and B cells, three major cell populations for the maintenance of pregnancy, demonstrate the role of this embryonic signal as a crucial immune regulator in the course of pregnancy. Human embryo rejection for hCG-related immunological reasons has been studied in different ways, and a sufficient dose of hCG seems to be necessary to maintain maternal tolerance. Different teams have studied the addition of hCG in patients suffering from recurrent miscarriages or implantation failures. hCG could also have a beneficial or a negative impact on autoimmune diseases during pregnancy. In this review, we will discuss the immunological impacts of hCG during pregnancy and if this hormone might be used therapeutically.

Indexed as

Abortion, SpontaneousAnimalsAutoimmune DiseasesAutoimmunityChorionic GonadotropinEmbryo TransferFemaleHumansImmunomodulationKiller Cells, NaturalPregnancyProtein IsoformsChorionic GonadotropinProtein IsoformsautoimmunityhCGimmunologyimplantationmiscarriagespregnancy

Identifiers

PMID32231662
PMCPMC7083149
OpenAlexW3012186015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.